Focus on FAPI Newsletter – Q4 2025
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI […]
SOFIE activates FAPI-GO, first [18F]FAPI-74 Phase 3 trial
Another defining moment for SOFIE Biosciences!
Last Friday, November 14, 2025, FAPI-GO, SOFIE’s [18F]FAPI-74 Phase 3 […]
Mosessian Named one of Top 25 Women Chief Scientific Officers in 2025
Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer, has been recognized by the […]
![FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494](https://sofie.com/wp-content/uploads/2025/12/info.ibamolecular-scaled.jpg)
FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients
Adrien Holzgreve, Lena M Unterrainer, Kimberly Flores, Ethan C Lam, Christine E Mona, Johannes Czernin, […]
68Ga-FAPI PET/CT Prevents Futile Surgery and Demonstrates Tumor Biology in Patients with Pancreatic Ductal Adenocarcinoma
William McGahan, Alexa Chadwick, Karen Lindsay, Brook Gulhane, Melissa J Latter, Thomas O’Rourke, Paul A […]
Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions
Sajjad Sadeghpour, Atena Aghaee, Hojjat Ahmadzadehfar, Alessio Rizzo, Giorgio Treglia, Ramin Sadeghi
![SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement](https://sofie.com/wp-content/uploads/2025/09/Graphic_EOP2-PR_News-Post.jpg)
SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement
- Favorable End-of-Phase 2 meeting with U.S. FDA for [18F]FAPI-74 for GI cancers
- Primary and […]
Focus on FAPI Newsletter – Q3 2025
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
![[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial](https://sofie.com/wp-content/uploads/2025/09/image.png)
[68Ga]Ga-API-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Kim M Pabst, Manuel M Weber, Christina Laschinsky, Patrick Sandach, Timo Bartel, Alina T Küper, […]
90 Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors
Helena Lanzafame, Christoph E Heilig, Eva Wardelmann, Mélanie Desaulniers, Kim Magaly Pabst, Ilektra Antonia Mavroeidi, […]